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BACKGROUND: Increasing pressures to provide high-quality evidence-based cancer care have driven the rapid proliferation of clinical
practice guidelines (CPGs). The quality and validity of CPGs have been questioned, and adherence to guidelines is relatively low. The
purpose of this study was to critically evaluate the development process and scientific content of CPGs. METHODS: CPGs addressing
management of rectal cancer were evaluated. We quantitatively assessed guideline quality with the validated Appraisal of Guidelines
Research & Evaluation (AGREE II) instrument. We identified 21 independent processes of care using the nominal group technique. We
then compared the evidence base and scientific agreement for the management recommendations for these processes of care.
RESULTS: The quality and content of rectal cancer CPGs varied widely. Mean overall AGREE II scores ranged from 27% to 90%. Across
the 5 CPGs, average scores were highest for the clarity of presentation domain (85%; range, 58% to 99%) and lowest for the applic-
ability domain (21%; range, 8% to 56%). Randomized controlled trials represented a small proportion of citations (median, 18%; range,
13%-35%), 78% of the recommendations were based on low- or moderate-quality evidence, and the CPGs only had 11 references
in common with the highest-rated CPG. There were conflicting recommendations for 13 of the 21 care processes assessed (62%).
CONCLUSIONS: There is significant variation in CPG development processes and scientific content. With conflicting recommendations
between CPGs, there is no reliable resource to guide high-quality evidence-based cancer care. The quality and consistency of CPGs
are in need of improvement. Cancer 2015;121:783-9. VC 2014 American Cancer Society.
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INTRODUCTION
There are increasing pressures to provide evidence-based cancer care and to document concordance with quality standards.
Recognizing these needs, there has been rapid proliferation of clinical practice guideline (CPG) recommendations over the last
decade.1 These CPGs aim to consolidate findings from increasingly expansive clinical research literature and to develop stand-
ardized approaches to high-quality care. However, concordance with guideline recommendations remains inadequate.2-4
Many have posited that clinicians’ lack of adherence to guidelines may be a result of distrust in how CPGs are devel-
oped and in the recommendations that are put forth.5 Developers of CPGs often fail to adhere to widely endorsed stand-
ards for the development of high-quality guidelines.6-9 These standards aim to improve the quality of CPGs, ensure
freedom from bias, and increase the likelihood of broad endorsement. Further, little attention has been given to disagree-
ment between CPGs in scientific content. Conflicting recommendations may result from either differences in the evidence
base used to synthesize recommendations or differences in interpretation of the same evidence. It is not known whether
adherence to standards for high-quality CPG development might be associated with the use of higher-quality evidence.
In this context, we sought to critically evaluate CPGs on the basis of their overall development quality, the evidence
base used to synthesize recommendations, and the scientific agreement between CPGs on key processes of care. An under-
standing of this relationship will help cancer care providers determine the reliability of CPG recommendations and better
inform their clinical decision making.
MATERIALS AND METHODS
In this study, we focused on recommendations for the management of rectal cancer. Rectal cancer requires well-
coordinated, multidisciplinary care and, given highly variable patient outcomes, is a disease site in need of more
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standardized care and promulgation of best practices. Fur-
ther, the evidence base for rectal cancer care is large and
diverse, ranging from expert opinion to results from
randomized controlled trials. This focus on 1 disease site
allows for in-depth evaluation of the quality and content
of specific care recommendations within the guidelines.
Five specialty societies or government-funded organi-
zations producing rectal cancer CPGs listed in the National
Guideline Clearinghouse and the Standards andGuidelines
Evidence databases were selected from 17 societies and
organizations via author consensus prior to data collection.
Only authoring organizations that published on the multi-
disciplinary management of rectal cancer were included.
The selected organizations and societies represent the key
authorities on rectal cancer care in North America and
Europe andwere believed to have credibility with large con-
stituencies; they are the, American Society of Colon and
Rectal Surgeons (ASCRS),10 Cancer Care Ontario
(CCO),11-14 European Society of Medical Oncology
(ESMO),15 National Comprehensive Cancer Network
(NCCN),16 and the National Institute for Health and Care
Excellence (NICE).17 The most up-to-date versions of the
CPG documents and the authoring organizations were
obtained from their respective websites. Only documents
published between 2008 and 2014 were included in the
analysis to ensure a contemporary comparison between
CPGs with access to a similar evidence base.
The process of development and quality of reporting
for each CPG was assessed using the Appraisal of Guide-
lines for Research & Evaluation (AGREE II) instru-
ment.18 The AGREE II is widely accepted as the
international gold standard for the appraisal of guide-
lines,19 developed by organizations in various settings.
The instrument is composed of 23 items within 6 quality
domains: 1) scope and purpose, 2) stakeholder involve-
ment, 3) rigor of development, 4) clarity of presentation,
5) applicability, and 6) editorial independence. Each item
is rated on a 7-point Likert scale. The AGREE II instru-
ment allows for up to 4 appraisers to independently rate
CPGs. Raters were blinded to each other’s ratings, and
achieved high interrater reliability, as evident by weighted
kappa scores of 0.7-0.9. The Likert ratings from all 4
raters were used to compute a standardized score from 0%
to 100% for each domain per AGREE standards. For
CPGs with multiple documents that address different
aspects of care (ie, CCO), the raters considered the docu-
ments collectively as one.
The CPG with the highest AGREE II 6-domain av-
erage was then used as the benchmark for comparing
process-of-care recommendations across CPGs. Using the
nominal group technique,20-22 we identified recom-
mended processes relevant to the care of rectal cancer,
across 5 clinical categories: 1) diagnosis and staging, 2)
preoperative therapy, 3) operative management, 4) post-
operative therapy, and 5) surveillance. The authors dis-
cussed each of the identified processes in a round-robin
feedback session, and were given the opportunity to clarify
their opinions regarding the relative importance of each
care process, including the option of adding processes that
were not initially identified. The authors then separately
prioritized the identified processes. Overlapping processes
of care were consolidated and ranked consecutively, and
those with broad consensus were included. A final list of
21 distinct processes of care was developed. This list was
redistributed to each panel member for approval. We eval-
uated the evidence used to inform recommendations for
each of the 21 processes of care and compared the cita-
tions, level of evidence (high- vs low- or moderate-quality
evidence), and the strength of the recommendations as
reported by the CPG authors to the highest-rated CPG.
The complete reference list for each CPG was man-
ually reviewed. Each citation was cross-checked with the
reference list of the highest-rated CPG to identify shared
references.
All statistical analyses were conducted using STATA
special edition (version 13; StataCorp, College Station,
TX).
RESULTS
Guideline Development: Organizational and
CPG Characteristics
The characteristics of the CPG authoring organization are
summarized in Table 1. Three are professional specialty
societies or consortiums (ASCRS, ESMO, and NCCN),
and 2 are government-associated multidisciplinary agencies
(NICE and CCO). In all authoring organizations, a panel
of individuals with clinical expertise was convened for the
synthesis of CPG recommendations. The CPG panel com-
prised a multidisciplinary membership in all but 1 organi-
zation because ASCRS included only colon and rectal
surgeons on its panel. Patient advocates were included on
the CCO, NCCN, and NICE panels, but not on the
ASCRS and ESMO panels. Financial support for the
guideline developmental process originated from either the
budget of professional organizations/societies (ASCRS,
ESMO, and NCCN) or grants issued by the government
or government-affiliated agencies (NICE and CCO).
Although the guidelines were developed over similar
periods, the evidence used to develop and justify treat-
ment recommendations differed. For example, the
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number of references ranged from 40 to 384 citations per
CPG. The methods for developing the CPGs specifically
included systematic reviews in the ASCRS, CCO, and
NICE guidelines, but ESMO and NCCN did not report
using systematic literature reviews as a part of their
process.
Guideline Development: AGREE II Scores
The AGREE II scores for each CPG in all 6 domains are
shown in Figure 1. Overall, rectal cancer CPGs from
NICE had the highest mean AGREE II score, 90%
(range by CPG, 27%-90%). In the scope and purpose
domain, only CCO and NICE clearly defined their
scope, global objectives, and target populations. For the
stakeholder involvement domain, only NICE and
NCCE included patients, their representatives, and
other stakeholders in the development of CPGs. The
biggest differences were seen in the rigor of the develop-
ment domain, with the NICE CPG scoring a 96% com-
pared with 17% for the ESMO guideline. Scores for the
TABLE 1. Organizational and Document Characteristics for Rectal Cancer Clinical Practice Guidelines
(CPGs)
Clinical Practice Guidelines Authoring Organization














Multidisciplinary Yes Yes No Yes Yes
Patient advocate Yes Yes No Yes No
Funding source Government Government Specialty society Specialty society Specialty society
Year published 2011 2008-2012 2013 2014 2013
Time frame for literature review 1806-2011 1999-2011 Through 2/2012 N/A N/A
Rectal cancer CPGs distinct
from colon cancer
No No Yes Yes Yes
Document length, pages 186 211 16 110 8
Number of references 245 206 154 486 40
Number of references
shared with NICE
[ref] 10 11 10 6
Percent of references from RCTs 21% 14% 18% 13% 35%
Disclosure statement Yes Yes No Yes Yes
Updating strategy Yes Yes No Yes No







Abbreviations: ASCRS, American Society of Colon and Rectal Surgeons; CCO, Cancer Care Ontario; ESMO, European Society of Medical Oncology; NCCN,
National Comprehensive Cancer Network; NICE, National Institute for Health and Care Excellence; RCTs, randomized controlled trials.
Figure 1. Comparison of the quality of the clinical practice guidelines using the AGREE II instrument. (ASCRS, American Society
of Colon and Rectal Surgeons; CCO, Cancer Care Ontario; ESMO, European Society of Medical Oncology; NCCN, National Com-
prehensive Cancer Network; NICE, National Institute for Health and Care Excellence).
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clarity of presentation domain were generally high in all
CPGs. In general, there was little information regarding
potential organizational barriers, cost implications, and
tools for application across all CPGs making the scores
for the applicability domain the lowest across all guide-
lines. Last, only CCO and NICE CPGs included clear
information about the potential conflicts of interest of
guideline institutions or members as presented in the
editorial independence domain scores.
Guideline Content: Scientific Agreement
The 21 processes of care are compared in Table 2. Overall,
the 5 CPGs had uniform agreement on their recommen-
dations in only 8 of the 21 processes of care (32%), as
described below. Of the 13 processes with disagreement, 6
recommendations were in direct conflict, and 7 were
actually nonrecommendations, reflecting a lack of direct
recommendations on a given issue.
Diagnosis and staging
Whereas all other CPGs defines rectal cancer as a tumor
located up to 15 cm from the anal verge on rigid proctos-
copy, thereby dividing the rectum into thirds, NCCN dif-
fers in its definition by limiting it to tumors 12 cm from
the anal verge. Although all CPGs recommend a complete
preoperative colonoscopic evaluation, only ASCRS,
ESMO, and NICE mention the role of CT colonography
as an alternative. ASCRS, NCCN and NICE CPGs rec-
ommend a CT scan of the chest, abdomen, and pelvis for
staging, but CCO and ESMO recommend an initial chest
x-ray, and ESMO recommends an abdominal ultrasound
orMRI to assess for liver metastases.
Preoperative therapy
All CPGs acknowledge the need for a multidisciplinary
tumor board for the management of rectal cancer patients
and that preoperative chemotherapy and/or radiation
TABLE 2. Scientific Content Comparison Between Clinical Practice Guidelines
Recommendations NICE CCO ASCRS NCCN ESMO
Diagnosis and staging
Thorough history and physical exam, rigid proctoscopy, CEA     
Complete preoperative colonoscopy with biopsy     
CT colonography as an alternative to colonoscopy   
Staging CT of chest, abdomen and pelvis, no additional staging imaging   
Pelvic MRI for all patients   
Recommend against routine PET imaging   
Preoperative enterostomal therapist consult   
Preoperative management
Discuss RC patients in a multidisciplinary tumor board     
Do not offer neoadjuvant therapy for low-risk resectable RC     
Consider SCRT with immediate surgery for moderate-risk RC  
Consider LCCRT with interval surgery for borderline moderate-high risk     
Offer LCRRT with interval surgery for high risk-operable cancer     
Operative management 
Offer local excision when feasible for low-risk T1 tumors with further therapy    
if high-risk features or compromised margins
Recommend laparoscopic surgery as an alternative to open surgery for patients  
suitable for both, and surgeons are appropriately trained
Adjuvant therapy
Assess pathologic staging after surgery before deciding whether to offer 
adjuvant therapy    
Offer adjuvant chemotherapy to patients who had surgery alone or had SCRT 
without chemotherapy    
Offer adjuvant chemotherapy in all patients who received neoadjuvant
chemotherapy or LCCRT
Surveillance
Start surveillance 4-6 weeks after potentially curative intervention   
Minimum 2 CT scans of the chest, abdomen and pelvis in the first 3 years and  
CEA every 6 months for the first 3 years  
Offer surveillance colonoscopy at 1 year; if normal repeat in 5 years  
Stop surveillance when patient and physician agree that the benefit no longer 
outweighs risk of tests, or patient cannot tolerate further therapy
Agreement in scientific content with the stated recommendation; a blank means that the guideline objectively disagrees or fails to mention the given recom-
mendation. Note ASCRS does not have surveillance recommendations published after 2008.
Abbreviations: ASCRS: American Society of Colon and Rectal Surgeons; CEA, carcinoembryonic antigen; CCO, Cancer Care Ontario; ESMO, European Soci-
ety of Medical Oncology; LCCRT, long-course chemoradiation therapy; NCCN: National Comprehensive Cancer Network; NICE, National Institute for Health
and Care Excellence; SCRT, short-course radiation therapy.
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therapy are not indicated in low-risk or stage I resectable
rectal cancer patients. The comparison highlights the dif-
ferences in practice between North America and Europe
in the use of short-course radiation therapy for moderate-
risk rectal cancer patients. However, all CPGs recom-
mend preoperative long-course chemoradiation therapy
for high-risk or advanced-stage patients.
Operative management
All CPGs advise the use of local excision techniques for
low-risk/stage I rectal cancer and recommend further
treatment if high-risk features are present on histopathol-
ogy. Only ASCRS and NICE recommend laparoscopic
rectal surgery as an alternative to the open approach. The
NCCN discusses the role of laparoscopic surgery but rec-
ommends its use only in the context of a clinical trial, and
CCO and ESMO do not specifically discuss the role of
laparoscopic surgery.
Adjuvant therapy
All other CPGs disagree with the NICE statement that
postoperative pathological staging is more important than
preoperative clinical staging in deciding whether to
administer postoperative chemotherapy. All CPGs agree
that patients with locally advanced or node-positive rectal
cancers who did not receive preoperative chemotherapy
should receive postoperative chemotherapy. However, the
CPGs differ in their interpretation of evidence regarding
indications for postoperative chemotherapy among
patients who received preoperative chemoradiation.
Although all CPGs reference the same publication by Bos-
sett and colleagues,23 NICE does not make a recommen-
dation because of insufficient evidence; CCO and NCCN
acknowledge the lack of evidence but recommend adju-
vant therapy based on expert consensus; ASCRS strongly
recommends adjuvant therapy and grades the evidence as
level 1A, and ESMO recommends adjuvant therapy and
grades the evidence as level 2B. Of note, ASCRS also cites
an additional subgroup analysis on this topic24; however,
a subgroup analysis does not meet criteria for level 1A evi-
dence, and the authors of that study appropriately caution
that their analysis is exploratory in nature.25
Surveillance
Only the NICE CPG clearly defines when surveillance
begins and ends. Although NICE, CCO, and NCCN rec-
ommend routine interval CT scans and CEA measure-
ments, ESMO reserves radiological and laboratory tests
for symptomatic patients only. ASCRS did not include
surveillance in this CPG version.
Quality of evidence
In all CPGs, the majority of evidence used to synthesize
the recommendations was of low-moderate quality
(Fig. 2). High-quality evidence (as graded by the author-
ing organizations) only comprised 22% of citations.
Figure 2. Distribution of the quality of evidence cited within each clinical practice guideline. Note: Cancer Care Ontario (CCO)
does not separately grade the evidence, and is therefore not included (ASCRS, American Society of Colon and Rectal Surgeons;
ESMO, European Society of Medical Oncology; NCCN, National Comprehensive Cancer Network; NICE, National Institute for
Health and Care Excellence).
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The guidelines appear to use a varied evidence base despite
a similar time frame for searching the evidence base. Using
the citations in the NICE CPG (which includes 245 refer-
ences) as the benchmark, the other documents only had 6
to 11 references in common with NICE.
DISCUSSION
This study sought to evaluate the quality and scientific
content of CPGs and compare the scientific basis for
guidelines issued by various organizations. Using a vali-
dated guideline appraisal instrument, we identified wide
differences in the quality of guideline development and
reporting for CPGs, with overall scores ranging from 26%
to 90%. The majority of the evidence that makes up the
CPGs was of low to moderate quality, and there were sub-
stantial differences in interpretation of data. There were
conflicting recommendations in 13 of the 21 specific
processes of care for rectal cancer that we examined.
We previously reported that oncology CPGs failed
to meet the Institute of Medicine’s standards for guideline
development.6 The present study demonstrates that these
inadequacies in development herald important differences
in the scientific content and the synthesized recommenda-
tions contained within CPGs. Although it is well known
that there is a relative paucity of high-quality evidence and
randomized controlled trials in cancer care, an end user
might expect that CPGs would examine the best available
evidence and draw similar conclusions. We found, how-
ever, that despite “systematic reviews” of the literature in
3 widely used CPGs, there were only 6-11 reference cita-
tions shared with the highest rated CPG. Furthermore,
even when using the same studies, CPGs interpreted their
conclusions differently, assigned them differing levels of
evidence quality, and formulated conflicting recommen-
dations. It is important that CPGs be transparent in their
methodology, clearly outlining areas in which evidence is
insufficient and in which expert opinion has been used.
For example, NICE and CCO are exemplars in this
regard, as their CPGs identify gaps in evidence and explic-
itly state when a recommendation is based on expert opin-
ion. Consensus statements may be appropriate when
evidence is lacking; however, some recommendations
within different CPGs are written with a degree of cer-
tainty that may be unwarranted given the lack of strong
evidence, leaving clinicians without reliable guidance.
There are differences in how organizations develop
guidelines. For example, the 2 highest-scoring CPGs were
authored by government-related organizations in countries
with nationally funded health systems. This is not surpris-
ing as broad-reaching policy decisions about resource allo-
cations for treatment warrant higher-quality guidelines.
Furthermore, the composition of the CPG development
groups varied considerably. Some included experts in a sin-
gle specialty, whereas others encompassed multiple special-
ties; some panels included patient advocates. This may
certainly influence what is included in the CPG documents
based on stakeholders’ perspectives. Even in panels with a
multidisciplinary structure, access to the necessary meth-
odological skills may have been limited. This highlights the
possible lack of adoption of a standardized CPG develop-
ment process and raises the question of whether greater
oversight is needed in this regard.
Generally speaking, CPGs with high scores on the
quality appraisal instrument performed consistently well in
most other domains, except for the applicability domain,
where most CPGs fell short. Lack of applicability could
mean that despite the vast resources that are invested into
developing CPGs, little consideration is given to how rec-
ommendations will be translated into practice. More efforts
may be needed to focus on understanding barriers to the
implementation of guidelines and how to better use evi-
dence to inform decisionmaking and treatment planning.
Because of increasing pressures to practice evidence-
based medicine and adhere to standards of care, CPGs have
become an increasingly important resource for clinicians.
However, the quality of the development process of the
guidelines is highly variable. More important, the content of
the resultant recommendations themselves is variable, and it
is possible that clinicians’ modest uptake of guideline recom-
mendations is directly related to perceptions that CPGs are
not of sufficient quality. The downstream implications for
measurement and possible enforcement of concordance with
guideline recommendations, as well as continued variation in
patient outcomes, are important to consider in this context.
Although the present study did not specifically address
the effect of the conflicting CPGs on practice patterns, there
is growing evidence that differences in practice are present
even when CPGs are in full agreement on a specific recom-
mendation. For example, Monson and colleagues26 recently
investigated variation in preoperative therapy for stage II/III
rectal cancer patients and found suboptimal adherence to
this recommendation, with significant differences based on
hospital volume and geographic regions. The present study
highlights some potential additional reasons for lack of ad-
herence to guidelines including the lack of a unified CPG
development process, conflicting recommendations, and
poor applicability of the produced CPGs.
This study has several limitations. By intent, the anal-
ysis presented here does not address rectal cancer guidelines
by all societies or organizations. CPGs that were not
Original Article
788 Cancer March 1, 2015
included may perform better or worse on the quality ap-
praisal instrument, but the comparison was limited to those
that are the most frequently used in clinical care, and our
findings are actually more likely to be generalizable because
of that. We did not examine guidelines for a wide range of
disease sites because of our focus on exact recommenda-
tions for specific processes of care, and rectal cancer is an
ideal example of the complex interplay between multiple
disciplines. Even though the study is limited in this regard,
it is probable that oncology CPGs for different disease sites
face similar challenges in their development and have simi-
lar deficiencies in evidence interpretation and scientific
content. Furthermore, we relied on materials reported in
the published versions of the CPGs, and our findings could
be affected not only by the quality of the guidelines them-
selves, but also by the quality of the reporting process.
Nonetheless, this also potentially puts the quality of the
reporting process under scrutiny.
In conclusion, there is significant variation in CPG
development processes, with associated differences in scien-
tific content and interpretation of evidence, resulting in
conflicting recommendations. These differences mean that
there may be no comprehensive resource available to guide
health care providers, which may limit the delivery of high-
quality evidence-based cancer care. Clinicians are advised
to be aware of potential gaps in evidence and conflicting
recommendations when using CPGs. If CPGs are to be
confidently used as standards of care going forward, guide-
line developers bear the burden of evaluating both their
processes and resultant end product, based on endorsed
standards for the development of high-quality guidelines.
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